-
1
المؤلفون: Thierry Maudelonde, Phillipe Rouanet, Jean Pierre Daures, Jean Grenier, Pascal Pujol, Jacques Bringer, Shine Chang, Jean Paul Brouillet
المصدر: Cancer. 91:1854-1861
مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Time Factors, medicine.drug_class, media_common.quotation_subject, Breast Neoplasms, Luteal phase, Cathepsin D, Follicle-stimulating hormone, Follicular phase, medicine, Humans, Prospective Studies, Survival rate, Menstrual Cycle, Progesterone, Menstrual cycle, media_common, Estradiol, business.industry, Luteinizing Hormone, Prognosis, Surgery, Survival Rate, Menstrual cycle phase, Premenopause, Receptors, Estrogen, Oncology, Estrogen, Multivariate Analysis, Female, Follicle Stimulating Hormone, Receptors, Progesterone, Breast carcinoma, business
الوصف: BACKGROUND Despite numerous studies, the influence of timing at surgery in relation to the menstrual cycle on the prognosis of breast carcinoma is still controversial. Most studies are retrospective, and the reliability of the menstrual history data is limited by the lack of hormonal assessment at the time of surgery. The authors prospectively studied the influence of the menstrual cycle phase as determined by circulating hormones at the time of surgery on the outcome of breast carcinoma. METHODS A population of 360 premenopausal women with nonmetastatic breast carcinoma operated on from 1992 to 1995 was analyzed. Serum estradiol, progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels were assayed the day of surgery to define the menstrual cycle phase (follicular, n = 186; ovulatory, n = 24; luteal, n = 150). The mean follow-up was 48 months. RESULTS There were no relations between the menstrual phase at surgery and tumor size, cathepsin D level, Scarff–Bloom–Richardson grade, Pg receptor (PgR), and the number of positive lymph nodes. The mean estrogen receptor level was higher during the follicular phase than in the ovulatory and luteal phases (P < 0.02). Univariate analysis of recurrence free survival (RFS) and overall survival (OS) showed no relations with the menstrual phase or the level of estradiol and progesterone at the time of surgery. High LH or FSH levels (above the medians) were associated with shorter RFS (P = 0.02 and P = 0.04, respectively) or OS (P ≤ 0.01 and P = 0.01, respectively). In multivariate analysis, lymph node status, PgR status and LH level were the most significant parameters for predicting OS. There appeared to be no survival differences between menstrual cycle groups after stratification by lymph node status. CONCLUSIONS This prospective study showed a lack of prognostic value of timing at surgery in relation to the menstrual period or to estrogen and progesterone levels in premenopausal breast carcinoma. Conversely, high gonadotropin levels could predict OS independently of other prognostic factors. Cancer 2001;91:1854–61. © 2001 American Cancer Society.
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f62c409b7b102021c9b1f0cf75fc0cb
https://doi.org/10.1002/1097-0142(20010515)91:10<1854::aid-cncr1206>3.0.co;2-y -
2
المصدر: Cancer. 74:1601-1606
مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, medicine.diagnostic_test, business.industry, medicine.drug_class, Incidence (epidemiology), Mammary gland, Estrogen receptor, Assay sensitivity, medicine.disease, Endocrinology, medicine.anatomical_structure, Breast cancer, Estrogen, Internal medicine, Progesterone receptor, Biopsy, medicine, business
الوصف: BACKGROUND The incidence of estrogen receptor (ER)-positive breast cancer apparently is increasing. It remains unclear whether this increase is due to an improvement in receptor assay sensitivity, a change in patient characteristics, or a change in tumor biology. METHODS The distribution of ER, tumor size, and patient age for 11,195 tumor specimens gathered from patients nationwide from 1973 to 1992 were analyzed. All assays were performed in a single laboratory. A single-label, dextran-coated charcoal (DCC) method was used from 1973 to 1984, and a dual-label, DCC method, which allows the determination of both ER and progesterone receptor levels in the same assay, was used from 1985 to 1992. RESULTS The median level of ER has increased steadily from 14 fmol per milligram of protein in 1973 to 58 fmol per milligram of protein in 1992 (P < 0.0001). The percentage of ER-positive tumors also rose from 73-78% during the same period (P = 0.008). When the assay method was modified from single to dual label, no abrupt or stepwise increase occurred. Tumor size decreased over the same period (P < 0.0001). From 1973 to 1977, 48% of tumors were larger than 2 cm, and 15% were larger than 5 cm, compared to 60% and 9%, respectively, from 1988 to 1992. The percentage of women older than 50 years of age remained relatively constant over time. After adjusting for tumor size, age, number of positive lymph nodes, and change in assay method, a sustained rise in ER level remained. In a multivariate analysis that included age, age group, year of biopsy, tumor size, and number of positive nodes, the year of biopsy still was independently predictive of ER level (P < 0.0001). CONCLUSION The measured level of ER in primary breast cancers has increased during the last 2 decades. It is unlikely that technical improvements or changes in tumor size, age, or nodal status fully explain this increase. The rising level of ER may reflect a change in breast cancer biology and in hormonal events that influence breast cancer genesis and growth.
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::212fccbd8a7db09a905ab3416277a266
https://doi.org/10.1002/1097-0142(19940901)74:5<1601::aid-cncr2820740517>3.0.co;2-# -
3
المؤلفون: Henri Rochefort, Thierry Maudelonde, Henri Pujol, Pascal Pujol, Jean-Pierre Daurès, Jean-Paul Brouillet, Philippe Rouanet
المصدر: Cancer. 71:2006-2012
مصطلحات موضوعية: Adult, Oncology, Cancer Research, medicine.medical_specialty, Pathology, Mammary gland, Cathepsin D, Breast Neoplasms, Metastasis, Cytosol, Breast cancer, Internal medicine, medicine, Adjuvant therapy, Humans, Prospective Studies, Prospective cohort study, Aged, Analysis of Variance, Univariate analysis, business.industry, Middle Aged, Progesterone Receptor Status, Prognosis, medicine.disease, Survival Rate, medicine.anatomical_structure, Lymphatic Metastasis, Female, business
الوصف: BACKGROUND Cathepsin D is a lysosomal protease overexpressed and abnormally secreted in most breast cancer cells. Several retrospective clinical studies have shown that cathepsin D is an independent prognostic factor in breast cancer that is associated with a higher risk of recurrence and a shorter overall survival. METHODS To the authors' knowledge, this is the first prospective study in which the prognostic value of cathepsin D was studied in 123 patients with primary breast cancer who were followed for 5 years between March 1985 and December 1990. Cathepsin D concentrations in breast cancer cytosol were measured using a solid-phase sandwich immunoenzymatic assay. The most significant prognostic factors were identified by multivariate analysis using the Cox proportional-hazards method. RESULTS The median value of cathepsin D was 20.8 pmol/mg of protein, which was approximately half than the median value found in subsequent assays done using a commercially available kit and reported in most retrospective studies. The cathepsin D status or level was correlated only with axillary lymph node involvement. A univariate analysis showed that high levels of cathepsin D (> 20 pmol/mg of protein) were correlated with a higher risk of recurrence and a shorter overall survival (P < 0.01 and P < 0.03, respectively). Using multivariate analysis, a high cathepsin D level, a negative progesterone receptor status, and lymph node involvement were the most important factors for predicting relapse-free survival (P = 0.02, P < 0.01, and P < 0.05, respectively). The cathepsin D level had prognostic value in patients with node-positive disease (P = 0.001) and appeared to be particularly useful in association with the progesterone receptor status by isolating a high-risk subgroup of patients (high cathepsin D level; negative progesterone receptor status). CONCLUSIONS This first prospective study confirmed the prognostic value of the cathepsin D level in association with other major prognostic factors. The next step will be to determine whether the subset of patients with high cathepsin D levels would benefit from adjuvant therapy.
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43446c0b15966570dc6b2c2a8dacec3c
https://doi.org/10.1002/1097-0142(19930315)71:6<2006::aid-cncr2820710614>3.0.co;2-q -
4
المؤلفون: Pascal Pujol, Isabelle Coupier, Mehrdad Noruzinia
المصدر: Cancer. 104(8)
مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Neoplasms, Hormone-Dependent, endocrine system diseases, medicine.drug_class, Genes, BRCA2, Genes, BRCA1, Estrogen receptor, Breast Neoplasms, Breast cancer, Internal medicine, medicine, Estrogen Receptor beta, Humans, Sporadic Breast Carcinoma, Genetic Predisposition to Disease, skin and connective tissue diseases, business.industry, Hereditary Breast Carcinoma, Estrogen Receptor alpha, Estrogens, medicine.disease, Antiestrogen, Gene Expression Regulation, Estrogen, Mutation, Cancer research, Female, business, Breast carcinoma, hormones, hormone substitutes, and hormone antagonists, Tamoxifen, medicine.drug
الوصف: Estrogen is a well known promoting factor of sporadic breast carcinoma. With regard to hereditary breast carcinoma, such as in BRCA1/BRCA2 syndromes, to date, the effects of estrogens on risk modification are not clear. Several studies have shown that prophylactic oophorectomy may decrease the risk of breast carcinoma in BRCA1/BRCA2 mutation carriers. Moreover, adjuvant tamoxifen therapy for primary breast carcinoma appears to diminish the risk of a second breast malignancy in BRCA1 mutation carriers. Conversely, exogenous estrogens, such as oral contraceptives, may increase the risk of breast carcinoma in familial breast cancer, as suggested by clinical studies. Paradoxically, the majority of BRCA1-related breast carcinomas are negative for ER. There is some biologic evidence of interactions between estrogens and BRCA proteins. BRCA1 expression could be induced by estradiol in experimental models, whereas recent studies indicate that BRCA1 modifies the regulatory effects of the estrogen receptor (ER) alpha (ERalpha). Prospective studies will be required to estimate the potential benefits of estrogen suppression therapies for the prevention and adjuvant treatment of BRCA1/BRCA2-related breast carcinomas.
-
5
المؤلفون: Jean-Pierre Daurès, Fançoise Guilleux, Jean Grenier, Simon Thezenas, Phillipe Rouanet, Pascal Pujol
المصدر: Cancer. 83(4)
مصطلحات موضوعية: endocrine system, Cancer Research, medicine.medical_specialty, medicine.drug_class, media_common.quotation_subject, Estrogen receptor, Breast Neoplasms, Luteal phase, Internal medicine, Follicular phase, medicine, Humans, Prospective Studies, skin and connective tissue diseases, Menstrual cycle, Menstrual Cycle, Progesterone, media_common, Estradiol, business.industry, Luteinizing Hormone, medicine.disease, Menstrual cycle phase, Menopause, Endocrinology, Oncology, Receptors, Estrogen, Estrogen, Female, Follicle Stimulating Hormone, business, Luteinizing hormone, Receptors, Progesterone, hormones, hormone substitutes, and hormone antagonists
الوصف: BACKGROUND Estrogen receptor (ER) and progesterone receptor (PgR) status at the time of breast carcinoma surgery is used as a marker of both prognosis and hormone dependency to guide adjuvant therapy. The authors studied the influence of hormonal milieu at the time of surgery on ER and PgR levels. METHODS A population of 2020 patients with breast carcinoma, including 575 premenopausal women, was analyzed. ER and PgR levels were determined by radioligand binding assays (cutoff values, 10 fmol/mg). Serum estradiol (E2), progesterone (Pg), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels obtained on the day of surgery were used to define the menstrual cycle phase in premenopause. RESULTS In premenopause, there was a higher proportion of ER positive (ER+) tumors in the follicular phase (62%, n = 316) than in the ovulatory phase (51%, n = 59) and the luteal phase (53%, n = 200, P = 0.03). The mean ER level was also higher in the follicular phase (30 fmol/mg) than in the ovulatory phase (20 fmol/mg) and the luteal phase (25 fmol/mg, P < 0.001). The percentage of PgR positive (PgR+) tumors tended to be higher in the ovulatory phase (85%) than in the follicular (78%) and luteal (72%) phases (P = 0.11). The mean PgR was also higher in the ovulatory phase (177 fmol/mg) than in the follicular and luteal phases (134 and 92 fmol/mg, respectively; P < 0.001). The percentage of ER+ tumors was higher among menopausal women than among premenopausal women (67% vs. 59%, respectively; P < 0.001). Conversely, the percentage of PgR+ tumors was lower among menopausal women than among premenopausal women (65% vs. 78%, respectively; P < 0.001). In premenopause, there was a weak negative correlation between ER and E2 levels. No correlations were found between levels of ER and Pg and levels of FSH and LH or among levels of PgR and E2, Pg, and FSH and LH in premenopausal and menopausal women. CONCLUSIONS Changes in ER and PgR levels in breast carcinoma during the menstrual cycle and menopause suggest that interpretations of hormone dependency on the basis of steroid receptor values should take into account hormonal status at the time of surgery. Cancer 1998;83:698-705. © 1998 American Cancer Society.
إعادة تعيين المنقحات
عرض المنقحات (%%عد%%)